SGLT2i as fourth-line therapy and risk of mortality, end-stage renal diseases and cardiovascular diseases in patients with type 2 diabetes mellitus.
CONCLUSION: Among T2DM patients initiating fourth-line therapy, SGLT2i users had significant benefits in lowering risk of CVD, and potential benefits in lowering risks of ESRD and all-cause mortality. SGLT2i was the preferred fourth-line glucose-lowering medication least likely to be associated with complication risks.
PMID: 33039672 [PubMed - as supplied by publisher]
Source: Diabetes and Metabolism - Category: Endocrinology Authors: Wong CKH, Tang EHM, Man KKC, Chan EWY, Wong ICK, Lam CLK Tags: Diabetes Metab Source Type: research
More News: Cardiology | Cardiovascular | Coronary Heart Disease | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | Heart Disease | Hong Kong Health | Insulin | Science | Sodium | Stroke | Study